Dennis Cho Sells 659 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 659 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total value of $10,983.96.

Twist Bioscience Stock Up 0.2 %

TWST opened at $45.52 on Friday. The stock’s 50 day moving average price is $43.65 and its 200-day moving average price is $45.43. Twist Bioscience Co. has a one year low of $15.85 and a one year high of $60.90.

Analyst Ratings Changes

TWST has been the subject of a number of recent research reports. Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Finally, Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.22.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of TWST. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. increased its stake in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the 2nd quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.